A carregar...
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease
BACKGROUND: Blocking of lymphocyte trafficking to bile ducts is a potential mechanism to alter the disease course of patients with primary sclerosing cholangitis (PSC). AIM: To describe the effect of the α(4)β(7) integrin antibody, vedolizumab, on liver biochemistry and disease activity in patients...
Na minha lista:
| Publicado no: | Aliment Pharmacol Ther |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5821055/ https://ncbi.nlm.nih.gov/pubmed/29377235 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14525 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|